Characterization of PDLIM2 in non-small cell lung cancer


Karam Ashouri, Harris Krause, Andrew Elliott, Stephen V. Liu, Patrick C. Ma, Balazs Halmos, Zhaoxia Qu, Gutian Xiao, Ari Vanderwalde, Jorge J. Nieva


  • PDZ and LIM domain protein 2 (PDLIM2) acts as tumor suppressor by downregulating NF-kB and STAT3 signaling, modulating inflammation, immune response, and cell survival.

  • Mouse models have demonstrated that downregulation of PDLIM2 leads to PD-1 immune blockade and chemotherapy resistance.

  • We characterized the genomic and immunological landscape of PDLIM2 expression in Adenocarcinoma non-small cell lung cancer (NSCLC).

Download Publication